CytomX Therapeutics, Inc. (CTMX)
2.34
+0.05
(+2.18%)
USD |
NASDAQ |
Oct 30, 16:00
2.37
+0.03
(+1.28%)
After-Hours: 20:00
CytomX Therapeutics Enterprise Value : 184.39M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | 184.39M |
| October 29, 2026 | 173.50M |
| October 28, 2026 | 188.75M |
| October 27, 2026 | 177.85M |
| October 26, 2026 | 159.33M |
| October 23, 2026 | 180.03M |
| October 22, 2026 | 206.18M |
| October 21, 2026 | 197.47M |
| October 20, 2026 | 221.43M |
| October 19, 2026 | 184.39M |
| October 16, 2026 | 171.32M |
| October 15, 2026 | 199.64M |
| October 14, 2026 | 160.42M |
| October 13, 2026 | 181.12M |
| October 12, 2026 | 201.82M |
| October 09, 2026 | 234.51M |
| October 08, 2026 | 212.72M |
| October 07, 2026 | 230.15M |
| October 06, 2026 | 232.33M |
| October 05, 2026 | 236.69M |
| October 02, 2026 | 232.33M |
| October 01, 2026 | 247.58M |
| September 30, 2026 | 267.19M |
| September 29, 2026 | 273.73M |
| September 28, 2026 | 260.66M |
| Date | Value |
|---|---|
| September 25, 2026 | 262.84M |
| September 24, 2026 | 273.73M |
| September 23, 2026 | 280.27M |
| September 22, 2026 | 315.13M |
| September 21, 2026 | 275.91M |
| September 18, 2026 | 275.91M |
| September 17, 2026 | 288.98M |
| September 16, 2026 | 277.00M |
| September 15, 2026 | 260.66M |
| September 14, 2026 | 371.78M |
| September 11, 2026 | 391.40M |
| September 10, 2026 | 404.47M |
| September 09, 2026 | 445.87M |
| September 08, 2026 | 469.84M |
| September 04, 2026 | 482.91M |
| September 03, 2026 | 476.38M |
| September 02, 2026 | 485.09M |
| September 01, 2026 | 474.20M |
| August 31, 2026 | 406.65M |
| August 28, 2026 | 373.96M |
| August 27, 2026 | 419.72M |
| August 26, 2026 | 397.93M |
| August 25, 2026 | 408.83M |
| August 24, 2026 | 391.40M |
| August 21, 2026 | 389.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 90.65B |
| ACADIA Pharmaceuticals, Inc. | 2.662B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 267.21M |
| Savara, Inc. | 847.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.67M |
| Revenue (Quarterly) | 1.418M |
| Total Expenses (Quarterly) | 22.08M |
| EPS Diluted (Quarterly) | -0.0944 |
| Gross Profit Margin (Quarterly) | 96.69% |
| Profit Margin (Quarterly) | -1.46K% |
| Earnings Yield | -19.53% |
| Normalized Earnings Yield | -19.55 |